Michael Girardi is a Dermatology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
15 York St
New Haven, CT 065103221
Telephone
203-785-4632Registry record last updated 1 Aug 2016.
Clinical trials
- Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Sponsor: Yale University
- A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
Sponsor: Yale University
- A Sunscreen Based on Bioadhesive Nanoparticles
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Therakos LLCProgram year20252 payments
- KYOWA KIRIN, INC.Program year20251 payment
- Mallinckrodt Hospital Products Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
33.4%Corticosteroid23.3%Triamcinolone Acetonide100%Part D≥55 patientsInterleukin-4 Receptor alpha Antagonist10.1%Dupixent Pen57%Dupixent Syringe43%Part D<11 patientsSensory organs
29.7%Corticosteroid29.7%Clobetasol Propionate77%Hydrocortisone23%Part D<11 patientsAnti-infectives
20.6%Azole Antifungal20.6%Ketoconazole100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 1998–2026 per NIH RePORTER. The latest:
- Bioengineering for Optimization of Locoregional Treatment of Advanced Melanoma
Yale University
FY2026$610,637R01CA292870
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”